ASA404: update on drug development.
作者： Farah Rehman , Gordon Rustin
DOI: 10.1517/13543784.17.10.1547
关键词:
摘要: Background: Interrupting tumour blood flow and delivery of nutrients to cause death is the aim antiangiogenic vascular disrupting agents (VDAs). ASA404 first VDA enter Phase III trials. Objective: We review preclinical clinical data on this interesting agent consider its place in modern therapeutics. Methods: PubMed database was searched for ‘ASA404’, ‘AS1404’, ‘DMXAA’, ‘vascular agents’, ‘ASA404 trials’, ‘AS1404 ‘DMXAA trials’. Results/conclusions: a that well tolerated has shown promise treatment NSCLC combination with paclitaxel carboplatin. A confirmatory trial currently ongoing.
sci-hub.se 参考文章(45)
H. Gabra, Phase II study of DMXAA combined with carboplatin and paclitaxel in recurrent ovarian cancer Journal of Clinical Oncology. ,vol. 24, pp. 5032- 5032 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.5032
George Pettit, S. A. Hill, D. J. Chaplin, Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Research. ,vol. 19, pp. 189- 195 ,(1999)
Zwi Lj, Baguley Bc, Gavin Jb, Wilson Wr, Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncology Research. ,vol. 6, pp. 79- 85 ,(1994)
D J Chaplin, G J Dougherty, Tumour vasculature as a target for cancer therapy. British Journal of Cancer. pp. 57- 64 ,(1999)
Mark J. McKeage, Joachim von Pawel, P3-116: Phase II study of DMXAA (AS1404) 1800 mg/m2 combined with carboplatin and paclitaxel in non-small cell lung cancer Journal of Thoracic Oncology. ,vol. 2, ,(2007) , 10.1097/01.JTO.0000284092.05580.83
A. M. Gaya, J. Violet, G. Dancey, A. Green, M. Stratford, S. Sharma, K. Owen, A. Padhani, G. J. Rustin, R. H. Begent, T. Meyer, A phase I/II trial of radioimmunotherapy with (131)Iodine labelled A5B7 anti-CEA antibody (I-131-A5B7) in combination with Combretastatin-A4-Phosphate (CA4P) in advanced gastrointestinal carcinomas Journal of Clinical Oncology. ,vol. 26, pp. 14517- 14517 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.14517
R. Pili, M. Rosenthal, , Randomized phase II study of docetaxel with or without DMXAA (AS1404) in hormone-refractory metastatic prostate cancer (HRMPC) Journal of Clinical Oncology. ,vol. 25, pp. 5115- 5115 ,(2007) , 10.1200/JCO.2007.25.18_SUPPL.5115
M. McKeage, Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. ,vol. 24, pp. 7102- 7102 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.7102
Mark J McKeage, Lloyd R Kelland, 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA) American Journal of Cancer. ,vol. 5, pp. 155- 162 ,(2006) , 10.2165/00024669-200605030-00002
Bruce C. Baguley, Wayne R. Joseph, Lai-Ming Ching, Kathryn E. Crosier, Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Research. ,vol. 54, pp. 870- 872 ,(1994)